PharmaJet Poster Presentation at Cancer Immunotherapy Conference Highlights How Needle-free Technology is Enhancing Oncology ...

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial ...

Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and ...

CHICAGO–(BUSINESS WIRE)–Tempus AI ... This year, highlights of Tempus’ poster presentations include: Poster Presentation ...

November 05, 2024--(BUSINESS WIRE)--ReAlta Life Sciences ... inflammatory response to address rare and acute inflammatory ...

On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory B ...

About NX-5948: NX-5948 is an investigational, orally bioavailable degrader of BTK that is currently being evaluated in a ...

Tickets are available – and registration will be open right up until the day of the event – for the 2024 Protein Science in ...

Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last ...

When it comes to artificial intelligence, Greg McFalls is one of the region’s foremost experts on engineering business solutions with a focus on safety, quality and productivity. That’s why the ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...